Online citations, reference lists, and bibliographies.

Alternative Approaches For PET Radiotracer Development In Alzheimer's Disease: Imaging Beyond Plaque.

J. Holland, S. Liang, Benjamin H Rotstein, T. Collier, Nickeisha A Stephenson, I. Gregurić, N. Vasdev
Published 2014 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Alzheimer's disease (AD) and related dementias show increasing clinical prevalence, yet our understanding of the etiology and pathobiology of disease-related neurodegeneration remains limited. In this regard, noninvasive imaging with radiotracers for positron emission tomography (PET) presents a unique tool for quantifying spatial and temporal changes in characteristic biological markers of brain disease and for assessing potential drug efficacy. PET radiotracers targeting different protein markers are being developed to address questions pertaining to the molecular and/or genetic heterogeneity of AD and related dementias. For example, radiotracers including [(11) C]-PiB and [(18) F]-AV-45 (Florbetapir) are being used to measure the density of Aβ-plaques in AD patients and to interrogate the biological mechanisms of disease initiation and progression. Our focus is on the development of novel PET imaging agents, targeting proteins beyond Aβ-plaques, which can be used to investigate the broader mechanism of AD pathogenesis. Here, we present the chemical basis of various radiotracers which show promise in preclinical or clinical studies for use in evaluating the phenotypic or biochemical characteristics of AD. Radiotracers for PET imaging neuroinflammation, metal ion association with Aβ-plaques, tau protein, cholinergic and cannabinoid receptors, and enzymes including glycogen-synthase kinase-3β and monoamine oxidase B amongst others, and their connection to AD are highlighted.
This paper references
10.1371/journal.pone.0039186
Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease
C. D'Addario (2012)
10.1016/j.bbr.2009.12.044
The history of the cholinergic hypothesis
A. Contestabile (2011)
10.1093/oxfordjournals.bmb.a073931
ADVANCES IN PHARMACOLOGY
H. Adam (1951)
10.1523/JNEUROSCI.0889-12.2012
Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease
David E Hurtado (2012)
10.1016/S0197-4580(00)00100-7
Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease
T. Thomas (2000)
10.1002/jlcr.3007
Radiochemistry devoted to the production of monoamine oxidase (MAO-A and MAO-B) ligands for brain imaging with positron emission tomography.
Ken Kersemans (2013)
10.1186/1742-2094-8-171
Neuroinflammation in Alzheimer's disease wanes with age
J. Hoozemans (2011)
10.1007/BF01731838
Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one
S. Bernard (2005)
10.1016/j.bmcl.2011.12.139
Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation.
J. W. Hicks (2012)
10.1016/J.BMCL.2005.08.037
Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies.
N. Vasdev (2005)
10.1007/s11307-005-0016-1
Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase
J. Fowler (2005)
10.2967/jnumed.111.092338
PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with 18F-AZAN, a Radioligand with Improved Brain Kinetics
H. Kuwabara (2012)
10.1111/j.1471-4159.2007.05194.x
The GSK3 hypothesis of Alzheimer's disease
C. Hooper (2008)
10.1016/j.nucmedbio.2007.12.009
Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors.
A. Wilson (2008)
10.1016/S0969-8051(00)00166-9
Pharmacological evaluation of [11C]donepezil as a tracer for visualization of acetylcholinesterase by PET.
F. de Vos (2000)
10.1126/science.3992249
Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.
D. Mash (1985)
10.1159/000067423
GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease
R. Bhat (2002)
10.1002/ana.20009
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
W. Klunk (2004)
10.1073/PNAS.0507053102
Predicting the energetics of osmolyte-induced protein folding/unfolding.
M. Auton (2005)
10.1093/brain/aws210
Decreased carbon-11-flumazenil binding in early Alzheimer's disease.
B. Pascual (2012)
10.1016/j.nucmedbio.2012.03.011
The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).
M. Skaddan (2012)
10.1016/J.MIBIO.2003.09.014
Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents.
R. Waterhouse (2003)
10.1002/jlcr.3008
PET radioligands targeting the brain GABAA /benzodiazepine receptor complex.
Jan D. Andersson (2013)
10.1002/(SICI)1098-2396(199602)22:2<123::AID-SYN5>3.0.CO;2-F
In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP).
M. Kilbourn (1996)
10.1016/j.bmc.2010.05.058
Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2).
A. Horti (2010)
Synthesis and Biodistribution of Radiolabeled α7 Nicotinic Acetylcholine Receptor Ligands
M. Pomper (2005)
10.1002/JLCR.1908
Radiosynthesis of [11C]SL25.1188 via [11C]CO2 fixation for imaging monoamine oxidase B
N. Vasdev (2011)
10.2967/jnumed.109.067108
In Vivo Tumor Grading of Prostate Cancer Using Quantitative 111In-Capromab Pendetide SPECT/CT
Y. Seo (2010)
10.1053/j.semnuclmed.2011.02.005
Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
S. Vallabhajosula (2011)
10.1039/C2MD20075A
Synthesis and PET imaging studies of [18F]2-fluoroquinolin-8-ol ([18F]CABS13) in transgenic mouse models of Alzheimer's disease
N. Vasdev (2012)
10.1016/j.apradiso.2008.12.015
An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP.
Erik M. van Oosten (2009)
10.1016/j.nucmedbio.2011.02.017
Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
Kristin McLarty (2011)
10.2967/JNUMED.111.088815
Reduction of radiation dose in PET-CT: Low dose protocols and image quality
A. Ettrup (2011)
10.1016/j.nucmedbio.2011.10.019
Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor.
N. Turkman (2012)
10.1074/jbc.M111.309385
γ-Aminobutyric Acid Type A (GABAA) Receptor Activation Modulates Tau Phosphorylation*
Niko-Petteri Nykänen (2012)
10.1007/s00259-011-2045-0
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
V. Villemagne (2011)
10.1002/JLCR.942
The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease
V. Papazian (2005)
10.1007/s00259-008-1031-7
Molecular imaging of α7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743
W. Deuther-Conrad (2008)
10.1111/j.1471-4159.2011.07237.x
Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer’s disease
R. Rissman (2011)
10.3389/fnagi.2010.00022
Microglial Activation and Neuroinflammation in Alzheimer's Disease: A Critical Examination of Recent History
W. Streit (2010)
10.1212/WNL.52.4.691
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease
D. Kuhl (1999)
10.1016/S0969-8051(98)00045-6
Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity.
S. Snyder (1998)
10.1002/jlcr.2995
Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors.
F. Sobrio (2013)
10.1002/jlcr.3020
Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors.
A. Horti (2013)
10.1097/00001756-199305000-00018
In vivo visualization of acetylcholinesterase with positron emission tomography.
B. Tavitian (1993)
10.1002/syn.20703
[(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate.
W. Saba (2010)
10.2967/jnumed.110.086629
The Translocator Protein
A. Scarf (2011)
10.1021/jm00169a034
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
A. Plenevaux (1990)
10.1016/j.jcmg.2011.11.024
Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo.
J. Bucerius (2012)
10.1016/j.bmc.2013.04.077
Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.
O. Sadovski (2013)
10.1006/exnr.2000.7397
On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis
R. Bartus (2000)
10.1371/journal.pbio.0050052
FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein
C. Westmark (2007)
10.1016/j.nurt.2008.05.001
Therapeutics for Alzheimer’s disease based on the metal hypothesis
A. Bush (2011)
10.1007/s12149-009-0240-x
Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography
J. Toyohara (2009)
10.1016/j.nucmedbio.2010.09.007
Biodistribution and radiation dosimetry of the α7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans.
M. Sakata (2011)
10.3233/JAD-2008-15208
Drug development based on the metals hypothesis of Alzheimer's disease.
A. Bush (2008)
10.1016/j.nucmedbio.2010.08.001
[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography.
A. Wilson (2011)
10.1523/JNEUROSCI.4717-09.2010
Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid β42 from Isolated Intact Nerve Terminals
S. H. Kim (2010)
10.1097/MNM.0b013e3283060c72
Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primates
Marie-José Bélanger (2008)
10.1002/jlcr.2989
Positron emission tomography radioligands for in vivo imaging of Aβ plaques.
N. Mason (2013)
10.2174/1389557043403332
Development of radioligands for in vivo imaging of GABA(A)-benzodiazepine receptors.
A. Katsifis (2004)
10.2967/jnumed.112.103846
PET Imaging of α4β2* Nicotinic Acetylcholine Receptors: Quantitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate
A. Hillmer (2012)
10.1016/S1474-4422(04)00853-1
PET imaging of amyloid in Alzheimer's disease
A. Nordberg (2004)
10.1186/2191-219X-1-6
Evaluation of 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging
Ritu Kant (2011)
10.1016/S0306-4522(02)00223-3
Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum
A. Graham (2002)
10.1126/science.7046051
The cholinergic hypothesis of geriatric memory dysfunction.
R. Bartus (1982)
10.1021/ML100190T
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
D. S. Johnson (2011)
10.1016/j.bmc.2011.07.062
Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.
N. Turkman (2011)
10.1016/j.bmcl.2012.11.066
The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor.
Alexander Jackson (2013)
10.1016/J.BMC.2006.10.038
ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.
S. Hintermann (2007)
10.2174/138161206778559678
Imaging of muscarinic receptors in the central nervous system.
W. Eckelman (2006)
10.1126/science.1411529
Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.
R. Nitsch (1992)
10.1007/978-3-642-55539-8_20
Monoamine oxidase: radiotracer development and human studies.
J. Fowler (2002)
10.1111/j.1471-4159.1988.tb01121.x
Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase‐Catalyzed Binding of [11C]l‐Deprenyl in Living Baboon Brain
J. Fowler (1988)
10.1016/S0140-6736(96)09124-6
Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease
M. Iyo (1997)
10.3233/JAD-2010-1390
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
N. Faux (2010)
10.1016/0165-6147(91)90609-V
Amyloid deposition as the central event in the aetiology of Alzheimer's disease.
J. Hardy (1991)
10.1038/nm0409-356
The curious case of clioquinol
L. Cahoon (2009)
10.1177/070674370404900705
GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia
K. Lanctôt (2004)
10.1021/ml300216t
Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.
X. Shao (2012)
10.1002/SYN.20147
Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers.
T. Hamill (2005)
10.1016/j.lfs.2009.02.029
Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.
A. Horti (2010)
10.1515/9783111697888-007
E
Adam S. Opalski (1824)
10.3233/JAD-2006-9S335
GSK-3 is essential in the pathogenesis of Alzheimer's disease.
A. Takashima (2006)
10.1016/0165-0173(95)00011-9
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
P. Mcgeer (1995)
10.1016/j.nucmedbio.2012.11.004
Evaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice.
C. C. Constantinescu (2013)
10.1016/S0140-6736(01)05625-2
In-vivo measurement of activated microglia in dementia
A. Cagnin (2001)
10.2741/3938
Metals in Alzheimer's disease: a systemic perspective.
R. Squitti (2012)
10.1073/pnas.1204606109
Loss of functional GABAA receptors in the Alzheimer diseased brain
A. Limon (2012)
10.2174/157015907780866884
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.
J. Ashton (2007)
10.1523/JNEUROSCI.23-35-11136.2003
Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains
C. Benito (2003)
10.1016/J.APRADISO.2004.02.026
Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease.
J. Schmaljohann (2004)
10.1002/jlcr.2992
The potential of carbon-11 and fluorine-18 chemistry: illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa.
Annelaure Damont (2013)
10.1111/j.1471-4159.2005.03335.x
Down‐regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease‐relevant genes and proteins
T. Zuchner (2005)
10.1111/j.1532-5415.1992.tb01992.x
The Mini‐Mental State Examination: A Comprehensive Review
T. Tombaugh (1992)
10.1126/science.3099392
Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.
J. Fowler (1987)
10.1038/nrn731
Ion channel structure: Emerging structure of the Nicotinic Acetylcholine receptors
A. Karlin (2002)
10.1016/j.jphysparis.2005.12.080
The role of nicotinic acetylcholine receptors in Alzheimer’s disease
S. Oddo (2006)
10.1016/0883-2889(91)90060-E
The synthesis of no-carrier-added DL-4-[18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction.
A. Plenevaux (1991)
10.1016/J.NUCMEDBIO.2003.09.003
Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET.
M. Mitterhauser (2004)
10.1139/V10-149
Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals — Radiosynthesis and ex vivo biodistribution of [18F]3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine
Erik M. van Oosten (2010)
10.1007/s00259-009-1066-4
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
S. Dedeurwaerdere (2009)
10.1016/j.bmc.2008.06.045
Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
Yedi Sun (2008)
10.1038/nm1423
Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model
J. McLaurin (2006)
10.1038/sj.npp.1300302
Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380
S. Pimlott (2004)
10.2217/FNL.12.34
The challenges of tau imaging
V. Villemagne (2012)
10.1124/pr.108.000562
Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection
S. Buckingham (2009)
Chem
A. Plenevaux (2015)
10.1016/J.APRADISO.2005.06.006
A rapid and efficient preparation of [123I]radiopharmaceuticals using a small HPLC (Rocket) column.
A. Katsifis (2006)
10.1124/JPET.105.090134
Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor
M. K. Grant (2005)
10.1016/j.neuint.2010.10.013
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography
B. Gulyás (2011)
10.1093/brain/awr038
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.
M. Fodero-Tavoletti (2011)
10.1016/S0028-3908(03)00050-9
Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice
E. Jagoda (2003)
10.1523/JNEUROSCI.3076-10.2011
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders
J. Maeda (2011)
10.1016/j.nucmedbio.2010.03.009
PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue.
Leonie Wyffels (2010)
10.1016/j.nucmedbio.2011.03.003
Development of new radiopharmaceuticals for imaging monoamine oxidase B.
Neil Vasdev (2011)
10.1039/C3MD00017F
Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of τ-pathology
Patrick J Riss (2013)
10.1002/SYN.20445
Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5.
Ji-Quan Wang (2007)
10.1016/0022-3956(75)90026-6
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
M. Folstein (1975)
10.1136/jnnp.66.2.137
The cholinergic hypothesis of Alzheimer’s disease: a review of progress
P. Francis (1999)
10.1021/jm7014556
Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography.
C. Fookes (2008)
10.1038/nature01640
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
C. Phiel (2003)
10.1016/j.bmcl.2011.06.048
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
Annelaure Damont (2011)
10.1016/j.bmc.2012.05.046
Development of new carbon-11 labelled radiotracers for imaging GABAA- and GABAB-benzodiazepine receptors.
M. D. Moran (2012)
10.1039/b913317h
Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol.
Neil Vasdev (2009)
10.2967/jnumed.112.107995
18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry
D. Wong (2013)
10.1016/j.neubiorev.2011.03.001
Revisiting the cholinergic hypothesis in the development of Alzheimer's disease
Laura A. Craig (2011)
10.1016/j.neuron.2010.01.016
Group 1 mGluR-Dependent Synaptic Long-Term Depression: Mechanisms and Implications for Circuitry and Disease
C. Lüscher (2010)
10.1007/s00259-009-1353-0
In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model
N. Van Camp (2009)
10.1016/j.bmc.2012.02.056
Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).
S. Nag (2012)
10.1093/brain/aws243
Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease.
A. Dorr (2012)
10.1016/j.bmcl.2012.08.022
Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[(18)F]fluoro-myo-inositol.
L. Carroll (2012)
10.1124/JPET.102.041616
The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development
A. Terry (2003)
10.2174/092986709788803150
Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography.
F. Dollé (2009)
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.
S. Ametamey (2006)
10.1097/00004647-199810000-00010
Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies
R. Carson (1998)
10.3390/molecules15118260
Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT
J. W. Hicks (2010)
10.1021/jm301492y
Radiosynthesis and Evaluation of [11C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography
A. Wilson (2013)
10.1002/jlcr.3002
PET probes for imaging brain acetylcholinesterase.
T. Kikuchi (2013)
10.1016/j.steroids.2011.06.012
Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO)
M. Wang (2011)



This paper is referenced by
10.1016/j.bmcl.2014.11.048
Radiosynthesis and ex vivo evaluation of [(18)F]-(S)-3-(6-(3-fluoropropoxy)benzo[d]isoxazol-3-yl)-5-(methoxymethyl)oxazolidin-2-one for imaging MAO-B with PET.
Justin Wesley Hicks (2015)
10.1002/EJOC.201500924
Direct [11C]Methylation of Amines from [11C]CO2 for the Synthesis of PET Radiotracers
F. Liger (2015)
10.2174/1573406413666171002120847
New Perspectives of Alzheimer Disease Diagnosis - the Most Popular and Future Methods.
Katarzyna Pietrzak (2018)
10.1101/cshperspect.a023721
Tau Positron Emission Tomography Imaging.
H. Kolb (2017)
Synthesis of a Fluorinated 8-hydroxyquinoline Derivative to Explore the Metal Hypothesis of Alzheimer's Disease
Alina R. Kassenbrock (2016)
10.1007/978-1-4939-7704-8
Biomarkers for Alzheimer’s Disease Drug Development
R. Perneczky (2018)
10.1177/1536012117717852
Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT
B. Rempel (2017)
10.2217/nmt.14.48
New tools for the evaluation of patients with neurodegenerative diseases.
B. Dickerson (2014)
10.3389/fneur.2018.00625
In vivo Imaging of Glial Activation in Alzheimer's Disease
P. Edison (2018)
Chapter 2 Imaging of neuroinflammation in Alzheimer ’ s disease , multiple sclerosis and stroke : recent developments in positron emission tomography
B. Janssen (2017)
10.23736/S0390-5616.16.03281-1
A review of the recent advances in neuroimaging of frontotemporal lobar degeneration.
Federico D’Agata (2017)
10.1021/acschemneuro.5b00055
PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates.
S. Liang (2015)
10.1021/jm5017544
Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future.
Manuela Ariza (2015)
10.1002/anie.201603797
Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.
S. Liang (2016)
10.1038/ncomms15761
Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
T. Collier (2017)
10.3390/molecules23020300
Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases
Tetsuro Tago (2018)
10.1177/1536012118792317
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
Vidya Narayanaswami (2018)
Chapter 8 Summary and Future Prospects
()
10.1002/ejoc.201901386
11C-Labeling: Intracyclic Incorporation of Carbon-11 into Heterocycles: 11C-Labeling: Intracyclic Incorporation of Carbon-11 into Heterocycles
François Mouton Liger (2019)
Phenotypic Impact of Genetic Risk Pathways for Alzheimer's Disease
D. Felsky (2016)
10.1177/1352458516674568
Imaging of microglial activation in MS using PET: Research use and potential future clinical application
L. Airas (2017)
10.1186/s12883-014-0169-0
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
Michael A. Castello (2014)
10.1002/glia.22978
In vivo imaging of microglial activation by positron emission tomography with [11C]PBR28 in the 5XFAD model of Alzheimer's disease
Nazanin Mirzaei (2016)
10.1016/j.bbadis.2015.11.011
Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography.
B. Janssen (2016)
Exploring Palladium-Mediated 11C/12C-Carbonylation Reactions : PET Tracer Development Targeting the Vesicular Acetylcholine Transporter
Sara Roslin (2017)
10.1038/ncomms5365
Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics.
Benjamin H Rotstein (2014)
Synthetic Approaches Towards a Radiofluorinated Agent for Imaging Alzheimer ’ s Disease
N. Vasdev (2015)
10.1002/jlcr.3404
Synthesis and preliminary characterization of radioiodinated benzofuran-3-yl-(indol-3-yl)maleimide derivatives as potential SPECT imaging probes for the detection of glycogen synthase kinase-3β (GSK-3β) in the brain.
Masahiro Ono (2016)
10.1186/1742-2094-11-25
Modulation of inflammation in transgenic models of Alzheimer’s disease
Amy M. Birch (2013)
10.1002/cmdc.201600223
A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety
Edgar Sawatzky (2016)
10.3389/fnagi.2015.00114
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
M. Vandal (2015)
10.1007/s11307-017-1085-7
Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET)
Shil Patel (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar